| pubmed-article:4509017 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:4509017 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:4509017 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:4509017 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:4509017 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:4509017 | lifeskim:mentions | umls-concept:C0010711 | lld:lifeskim |
| pubmed-article:4509017 | lifeskim:mentions | umls-concept:C0042679 | lld:lifeskim |
| pubmed-article:4509017 | lifeskim:mentions | umls-concept:C0035052 | lld:lifeskim |
| pubmed-article:4509017 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:4509017 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:4509017 | pubmed:dateCreated | 1973-2-15 | lld:pubmed |
| pubmed-article:4509017 | pubmed:abstractText | A regimen of intravenous cyclophosphamide, cytarabine and vincristine, given over a four-day period and repeated every two to three weeks, was used to treat 33 patients with acute myeloblastic leukemia. Of the 30 evaluable patients 9/18 previously untreated patients achieved complete remission and two others marked improvement, and 4/12 previously treated patients achieved complete remission. Twelve of 16 patients under the median age of 38 responded while only 3/14 patients over this age responded. There was no difference in response between those with elevated muramidase levels and those with normal levels. Three patients developed a previously unrecognized syndorme of fever, malaise, rash and orbital suffusion. Cytarabine was probably responsible.At least four courses of treatment are required before abandoning this regimen of therapy. Patients who achieve a complete remission and live for more than 150 days spend about 25% of their total survival time from diagnosis in hospital. | lld:pubmed |
| pubmed-article:4509017 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:language | eng | lld:pubmed |
| pubmed-article:4509017 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:4509017 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:4509017 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:4509017 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:4509017 | pubmed:issn | 0008-4409 | lld:pubmed |
| pubmed-article:4509017 | pubmed:author | pubmed-author:CowanD HDH | lld:pubmed |
| pubmed-article:4509017 | pubmed:author | pubmed-author:HasselbackRR | lld:pubmed |
| pubmed-article:4509017 | pubmed:author | pubmed-author:BergsagelD... | lld:pubmed |
| pubmed-article:4509017 | pubmed:author | pubmed-author:ClarysseAA | lld:pubmed |
| pubmed-article:4509017 | pubmed:author | pubmed-author:Abu-ZahraHH | lld:pubmed |
| pubmed-article:4509017 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:4509017 | pubmed:day | 9 | lld:pubmed |
| pubmed-article:4509017 | pubmed:volume | 107 | lld:pubmed |
| pubmed-article:4509017 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:4509017 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:4509017 | pubmed:pagination | 1073-8 | lld:pubmed |
| pubmed-article:4509017 | pubmed:dateRevised | 2010-6-22 | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:meshHeading | pubmed-meshheading:4509017-... | lld:pubmed |
| pubmed-article:4509017 | pubmed:year | 1972 | lld:pubmed |
| pubmed-article:4509017 | pubmed:articleTitle | Treatment of acute myeloblastic leukemia in adults: remission induction with a combination of cyclophosphamide, cytarabine and vincristine. | lld:pubmed |
| pubmed-article:4509017 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:4509017 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:4509017 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:4509017 | lld:pubmed |
